Animalcare Group (ANCR) Fair Value & Analysis
Healthcare · GB · Market cap 230M GBX
Fair value as of: Jul 13, 2026
From 26 valuation models · updated 28 days ago
Share price +0.3% over the past month.
A solid business, but screening 59% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (£1.72). The favourable scenario is already priced in.
- Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 13, 2026.
How to read this chart
60‑month range £1.38 – £3.83 · fair‑value band £1.02 – £1.72 · the £3.34 price screens above the £1.38 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 13, 2026.
Analysis
Animalcare Group (ANCR) currently trades at £3.34, while our model-based Fair Value estimate is £1.38, implying the stock looks roughly 58.7% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Animalcare Group generated revenue of £89.1M at a net margin of 5.7%. Revenue grew 21.5% year over year. It earns a return on equity of 4.5%. Net debt stands at £12.3M. Fundamentals as of Jul 13, 2026
Our scenario range runs from £1.02 (bear case) to £1.72 (bull case); at £3.34, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -59%, ANCR screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (£2.13) versus Dividend Discount (£0.5700). Highest evidence: Growth DCF (80).
Notify me when ANCR reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 66
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Animalcare Group plc develops, sells, and distributes licensed veterinary pharmaceuticals for the companion animal, production animal, and equine veterinary markets in Europe, the Asia-Pacific, and internationally. It operates through Animalcare Europe and Randlab segments.
Full company description
Animalcare Group plc develops, sells, and distributes licensed veterinary pharmaceuticals for the companion animal, production animal, and equine veterinary markets in Europe, the Asia-Pacific, and internationally. It operates through Animalcare Europe and Randlab segments. The company offers Orozyme, an enzymatic toothpaste for dental care in cats and dogs; Danilon, an oral treatment for pain in horses; Dinalgen, an injectable treatment for pain in cattle, pigs, and horses; Aqupharm, a dehydration treatment for cats, dogs, cattle, goats, horses, pigs, rabbits, and sheep; Ulcershield, a treatment and prevention of gastric ulcers in horses; Daxocox, a treatment of osteoarthritis pain and inflammation in dogs; Plaqtiv+, a biofilm-based dental care for cats and dogs; Thiamacare, a treatment for hyperthyroidism in cats; Hemo, an injectable nutritional solution for horses; and Cosequin, a complementary feed for dogs and cats to strengthen and protect joints. It also provides nutritional supplements for the equine market; and professional support services to equine veterinarians. The company exports its products to approximately 45 countries. It has a collaboration with 272Bio to develop and commercialize a novel biological treatment for equine sweet itch. Animalcare Group plc is based in York, the United Kingdom.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Animalcare Group reported revenue of £89.1M in FY2025 versus £74.0M in FY2021, a compound +4.7%/yr. Reported net income was £5.1M in FY2025.
of which total revenue +21.5 pp · buybacks/dilution −0.8 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
ANCR screens 59% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Animalcare Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Animalcare Group (ANCR) overvalued or undervalued?
What is the fair value of ANCR?
What is the quality score of ANCR?
What is the revenue of Animalcare Group (ANCR)?
What is the net profit margin of ANCR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Animalcare Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.